TELA Bio Inc
NASDAQ:TELA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
TELA Bio Inc
Cash from Operating Activities
TELA Bio Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
TELA Bio Inc
NASDAQ:TELA
|
Cash from Operating Activities
-$28.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Cash from Operating Activities
$338.8m
|
CAGR 3-Years
9%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Cash from Operating Activities
$179.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-4%
|
CAGR 10-Years
13%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Cash from Operating Activities
$593.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Cash from Operating Activities
$390.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
88%
|
CAGR 10-Years
33%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Cash from Operating Activities
$297.4m
|
CAGR 3-Years
38%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
TELA Bio Inc
Glance View
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 123 full-time employees. The company went IPO on 2019-11-08. The firm is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. The company offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), is used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. Its OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. Its subsidiary include TELA Bio Limited.
See Also
What is TELA Bio Inc's Cash from Operating Activities?
Cash from Operating Activities
-28.2m
USD
Based on the financial report for Dec 31, 2025, TELA Bio Inc's Cash from Operating Activities amounts to -28.2m USD.
What is TELA Bio Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-3%
Over the last year, the Cash from Operating Activities growth was 32%. The average annual Cash from Operating Activities growth rates for TELA Bio Inc have been 12% over the past three years , -3% over the past five years .
